| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/17/2002 | CN1082963C Isoxazolidine derivatives |
| 04/17/2002 | CN1082961C Novel use and novel derivatives of imidazole, method for preparing same, novel intermediates thus obtained, medicinal and applications as medicine and pharmaceutical compositions thereof |
| 04/17/2002 | CN1082815C 吲哚衍生物 Indole derivatives |
| 04/16/2002 | US6372957 Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use |
| 04/16/2002 | US6372777 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/16/2002 | US6372768 2-aminopyridines containing fused ring substituents |
| 04/16/2002 | US6372767 Benzanilides as potassium channel openers |
| 04/16/2002 | US6372762 Heterocyclic compounds for nervous system disorders |
| 04/16/2002 | US6372757 Phenylurea and phenylthio urea derivatives |
| 04/16/2002 | US6372754 Drugs for treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpic neuralgia. |
| 04/16/2002 | US6372751 Drugs with benzene and pyrimidine rings |
| 04/16/2002 | US6372743 Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
| 04/16/2002 | US6372738 Cytotoxic agents comprising taxanes and their therapeutic use |
| 04/16/2002 | US6372731 Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments |
| 04/16/2002 | US6372726 Methods of cancer treatment using NAALADase inhibitors |
| 04/16/2002 | US6372724 Modulation of human mast cell activation |
| 04/16/2002 | US6372719 ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| 04/16/2002 | US6372490 Nucleic acid encoding the MDM interacting protein |
| 04/16/2002 | US6372462 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius |
| 04/16/2002 | US6372433 Antisense modulation of inhibitor of DNA binding-1 expression |
| 04/16/2002 | US6372267 Cocoa solids prepared by heating, pressing, recovering partially defatted cocoa solids which contain cocoa polyphenols including cocoa procyanidins |
| 04/16/2002 | US6372262 Serum-derived factor inducing cell differentiation and medical uses thereof |
| 04/16/2002 | US6372207 IFNAR2/IFN complex |
| 04/16/2002 | CA2260413C Terpenoid lactone compounds and their production process |
| 04/16/2002 | CA2218552C Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| 04/16/2002 | CA2217601C Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| 04/16/2002 | CA2088980C Pro-drugs for cck antagonists |
| 04/15/2002 | WO2002030514A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/15/2002 | CA2421622A1 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/11/2002 | WO2002029418A1 Selective anxiolytic therapeutic agents |
| 04/11/2002 | WO2002029403A1 Gata-3 expression inhibitor and method of screening the same |
| 04/11/2002 | WO2002029090A1 Subsance inhibiting the binding of signal transducing molecule to kdr/flk-1 phosphorylated at tyrosine at the 1175-position and method of using the same |
| 04/11/2002 | WO2002029088A2 Highly expressible genes |
| 04/11/2002 | WO2002029060A2 Hematopoietin receptors hpr1 and hpr2 |
| 04/11/2002 | WO2002029053A1 Novel g protein-coupled receptor protein and dna thereof |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002028906A2 Regulation of human sphingosine kinase-like protein |
| 04/11/2002 | WO2002028905A2 Human anti-cd40 antibodies |
| 04/11/2002 | WO2002028904A2 Human anti-cd40 antibodies |
| 04/11/2002 | WO2002028894A1 Gene relating to drug tolerance and utilization thereof |
| 04/11/2002 | WO2002028874A2 Tumor proliferation inhibitors |
| 04/11/2002 | WO2002028872A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 04/11/2002 | WO2002028865A2 Condensed pyridoindole derivatives |
| 04/11/2002 | WO2002028862A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 04/11/2002 | WO2002028859A2 Condensed pyridoindole derivatives |
| 04/11/2002 | WO2002028858A2 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 04/11/2002 | WO2002028856A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/11/2002 | WO2002028851A1 7-carboxy-flavone derivatives, preparation method and therapeutic use |
| 04/11/2002 | WO2002028842A2 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 04/11/2002 | WO2002028839A1 Benzimidazole and indole derivatives as crf receptor modulators |
| 04/11/2002 | WO2002028837A1 Metabotropic glutamate receptor antagonists |
| 04/11/2002 | WO2002028836A1 Novel crystalline forms of a factor xa inhibitor |
| 04/11/2002 | WO2002028835A1 Benzamide compounds as apo b secretion inhibitors |
| 04/11/2002 | WO2002028831A1 Inhibitors of prenyl-protein transferase |
| 04/11/2002 | WO2002028830A1 Novel phenylalanine derivatives |
| 04/11/2002 | WO2002028825A2 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 04/11/2002 | WO2002028824A1 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 04/11/2002 | WO2002028810A2 Retinoids for the treatment of emphysema |
| 04/11/2002 | WO2002028481A2 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 04/11/2002 | WO2002028480A2 Methods of therapy for b-cell malignancies |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028434A2 Use of a ppar delta activator for treating inflammatory conditions |
| 04/11/2002 | WO2002028433A2 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 04/11/2002 | WO2002028431A1 Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient |
| 04/11/2002 | WO2002028430A2 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 04/11/2002 | WO2002028418A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/11/2002 | WO2002028408A2 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 04/11/2002 | WO2002028406A2 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 04/11/2002 | WO2002028399A1 Apoptosis inducers, caspase cascade activators and anticancer agents |
| 04/11/2002 | WO2002028393A1 Use of neuropeptide-y antagonists in treatment of alcoholism |
| 04/11/2002 | WO2002028390A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | WO2002028381A2 Methods of inducing cancer cell death and tumor regression |
| 04/11/2002 | WO2002028378A1 Combination particles for the treatment of asthma |
| 04/11/2002 | WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | WO2002028373A1 New pharmaceutical compositions containing epinastine and pseudoephedrine |
| 04/11/2002 | WO2002028355A2 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | WO2002028349A2 Method of treating cancer using dithiocarbamate derivatives |
| 04/11/2002 | WO2002028346A2 Association of the cb1 receptor antagonist and sibutramin, for treating obesity |
| 04/11/2002 | WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | WO2002012275A3 Lat peptides and their use in assays for identifying immunosuppressants |
| 04/11/2002 | WO2002007533A3 Nutritional composition |
| 04/11/2002 | WO2002004531A3 Process for preparing benzoxazin-4-one polymer conjugates |
| 04/11/2002 | WO2001092308A3 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 04/11/2002 | WO2001090070A3 Caspase inhibitors and uses thereof |
| 04/11/2002 | WO2001090069B1 Novel calcium receptor active molecules and method for preparing same |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001085671A3 Anthranyl amides and their use as medicaments |
| 04/11/2002 | WO2001083450A3 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 04/11/2002 | WO2001078680A3 Pharmaceutical compositions comprising fluvastatin |
| 04/11/2002 | WO2001077079A3 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 04/11/2002 | WO2001076572A3 Use of compatible solutes as substances having free radical scavenging properties |
| 04/11/2002 | WO2001075107A3 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis |
| 04/11/2002 | WO2001074856A3 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 04/11/2002 | WO2001070174A3 Vegf-modulated genes and methods employing them |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001053348A3 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 04/11/2002 | WO2001049278A3 Compounds and compositions for use in inhibiting endoparasitic fatty acid biosynthesis |
| 04/11/2002 | WO2001019797A3 HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 04/11/2002 | WO2001010906A9 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 04/11/2002 | WO2000052210A3 Methods for targeting rna molecules |